Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of €1,000,000,000 with The Bank of New York Mellon, as trustee at 4.125% maturing June 1, 2031.
- Instrument
- senior notes
- Principal
- €1,000,000,000
- Counterparty
- The Bank of New York Mellon, as trustee
- Rate
- 4.125%
- Maturity
- June 1, 2031
- Event
- incurrence
Exact text from the filing
On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of $500,000,000 with The Bank of New York Mellon, as trustee at 6.000% maturing December 1, 2032.
- Instrument
- senior notes
- Principal
- $500,000,000
- Counterparty
- The Bank of New York Mellon, as trustee
- Rate
- 6.000%
- Maturity
- December 1, 2032
- Event
- incurrence
Exact text from the filing
On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).
View on SEC.gov